Associate Director, Sales Analytics and Operations

Redwood City, California, United States

Auto‑apply with AI Apply

$60,000 – $90,000Compensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Biotechnology, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree in a related field, such as Business, Finance, Statistics, or Economics, with a minimum of 7 years of experience in sales analytics and operations, preferably within the pharmaceutical or biotechnology industry. Strong analytical and problem-solving skills are essential, along with demonstrated leadership experience and a deep understanding of sales force management principles.

Responsibilities

As an Associate Director, Sales Analytics and Operations, you will lead the development and implementation of a targeting strategy to identify key physicians and accounts for the sales team, design the size and structure of future field teams, and partner with sales leadership to create compelling incentive compensation plans. You will also play a crucial role in ensuring anito-cel is delivered to multiple myeloma patients, collaborating with cross-functional teams and commercialization partners to drive strategic decisions and optimize sales performance.

Skills

Sales Analytics

Sales Operations

Sales Force Management

Targeting Strategy

Incentive Compensation

Cross-functional Collaboration

Strategic Decision-Making

Data Analysis

Problem-Solving

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free